Pancreatic cancer (PC) is a serious malignant tumor with a high mortality rate, mainly due to late diagnosis and a lack of effective therapeutic interventions. The possibility of recognizing this cancer with reliable biomarkers using minimally invasive methods is of great importance for improving early detection, prognostic assessment, and targeted treatment methods. In recent years, small non-coding RNAs, especially microRNAs, have emerged as promising candidates for biomarkers of pancreatic cancer. Despite the methodological and analytical limitations of microRNA determination and a lack of available automated and standardized tests, a prospective systematic assessment of this new parameter’s use in the detection of pancreatic cancer is warranted. This review provides general information on the diagnostic and prognostic utility of microRNAs, which appear to be well-established in many studies. In summary, microRNAs are promising non-invasive biomarkers of pancreatic cancer, offering potential opportunities for early detection, prognosis, and treatment monitoring. As research in this field progresses, microRNAs should become valuable tools in the fight against pancreatic cancer.
胰腺癌是一种死亡率极高的严重恶性肿瘤，主要归因于诊断延迟及缺乏有效治疗手段。通过微创方法利用可靠生物标志物识别该癌症的可能性，对于改善早期检测、预后评估及靶向治疗方法具有重要意义。近年来，小分子非编码RNA，特别是微小RNA，已成为胰腺癌生物标志物的潜在候选者。尽管微小RNA检测存在方法学和分析学上的局限性，且缺乏可用的自动化标准化检测方法，但对该新参数在胰腺癌检测中应用的前瞻性系统评估仍有必要。本综述概述了微小RNA在诊断和预后方面的应用价值，该价值已在多项研究中得到充分证实。总体而言，微小RNA作为胰腺癌的非侵入性生物标志物前景广阔，为早期检测、预后判断和治疗监测提供了潜在机遇。随着该领域研究的深入，微小RNA有望成为对抗胰腺癌的重要工具。
肿瘤(癌症)患者之家